Measuring inconsistency in meta-analyses
Reads0
Chats0
TLDR
A new quantity is developed, I 2, which the authors believe gives a better measure of the consistency between trials in a meta-analysis, which is susceptible to the number of trials included in the meta- analysis.Abstract:
Cochrane Reviews have recently started including the quantity I 2 to help readers assess the consistency of the results of studies in meta-analyses. What does this new quantity mean, and why is assessment of heterogeneity so important to clinical practice?
Systematic reviews and meta-analyses can provide convincing and reliable evidence relevant to many aspects of medicine and health care.1 Their value is especially clear when the results of the studies they include show clinically important effects of similar magnitude. However, the conclusions are less clear when the included studies have differing results. In an attempt to establish whether studies are consistent, reports of meta-analyses commonly present a statistical test of heterogeneity. The test seeks to determine whether there are genuine differences underlying the results of the studies (heterogeneity), or whether the variation in findings is compatible with chance alone (homogeneity). However, the test is susceptible to the number of trials included in the meta-analysis. We have developed a new quantity, I 2, which we believe gives a better measure of the consistency between trials in a meta-analysis.
Assessment of the consistency of effects across studies is an essential part of meta-analysis. Unless we know how consistent the results of studies are, we cannot determine the generalisability of the findings of the meta-analysis. Indeed, several hierarchical systems for grading evidence state that the results of studies must be consistent or homogeneous to obtain the highest grading.2–4
Tests for heterogeneity are commonly used to decide on methods for combining studies and for concluding consistency or inconsistency of findings.5 6 But what does the test achieve in practice, and how should the resulting P values be interpreted?
A test for heterogeneity examines the null hypothesis that all studies are evaluating the same effect. The usual test statistic …read more
Citations
More filters
Journal ArticleDOI
Problems with use of composite end points in cardiovascular trials: systematic review of randomised controlled trials
Ignacio Ferreira-González,Gaiet Permanyer-Miralda,Antònia Domingo-Salvany,Jason W. Busse,Diane Heels-Ansdell,Victor M. Montori,Elie A. Akl,Dianne Bryant,Pablo Alonso-Coello,Jordi Alonso,Andrew Worster,Suneel Upadhye,Roman Jaeschke,Holger J. Schünemann,Valeria Pacheco-Huergo,Ping Wu,Edward J Mills,Gordon H. Guyatt +17 more
TL;DR: The use of composite end points in cardiovascular trials is frequently complicated by large gradients in importance to patients and in magnitude of the effect of treatment across component end points.
Journal ArticleDOI
Relation of active, passive, and quitting smoking with incident type 2 diabetes: a systematic review and meta-analysis
TL;DR: A meta-analysis of prospective studies to investigate the associations between various smoking behaviours and diabetes risk estimated that 11·7% of cases of type 2 diabetes in men and 2·4% in women were attributable to active smoking.
Journal ArticleDOI
A Systematic Review of African Studies on Intimate Partner Violence against Pregnant Women: Prevalence and Risk Factors
TL;DR: Meta-analysis of prevalence data and reported odds ratios of risk factors demonstrated strong evidence that a history of violence is significantly associated with IPV in pregnancy and alcohol abuse by a partner also increases a woman's chances of being abused during pregnancy.
Journal ArticleDOI
Intimate partner violence victimization and alcohol consumption in women: a systematic review and meta‐analysis
Karen Devries,Jennifer C. Child,Loraine J. Bacchus,Joelle Mak,Gail Falder,Kathryn Graham,Charlotte Watts,Lori Heise +7 more
TL;DR: There is a clear positive association between alcohol use and intimate partner physical or sexual violence victimization among women, suggesting a need for programming and research that addresses this link, however, the temporal direction of the association remains unclear.
Journal ArticleDOI
Vitamin D and Cardiovascular Outcomes: A Systematic Review and Meta-Analysis
Mohamed B. Elamin,Nisrin O. Abu Elnour,Khalid B. Elamin,Mitra M. Fatourechi,Aziz A. Alkatib,Jaime P. Almandoz,Hau Liu,Melanie A. Lane,Rebecca J. Mullan,Ahmad Hazem,Patricia J. Erwin,Donald D. Hensrud,Mohammad Hassan Murad,Victor M. Montori +13 more
TL;DR: Trial data available to date are unable to demonstrate a statistically significant reduction in mortality and cardiovascular risk associated with vitamin D, and the quality of the available evidence is low to moderate at best.
References
More filters
Journal ArticleDOI
Quantifying heterogeneity in a meta‐analysis
TL;DR: It is concluded that H and I2, which can usually be calculated for published meta-analyses, are particularly useful summaries of the impact of heterogeneity, and one or both should be presented in publishedMeta-an analyses in preference to the test for heterogeneity.
Journal ArticleDOI
The combination of estimates from different experiments.
TL;DR: The problem of making a combined estimate has been discussed previously by Cochran and Yates and Cochran (1937) for agricultural experiments, and by Bliss (1952) for bioassays in different laboratories as discussed by the authors.
Journal ArticleDOI
Tamoxifen for early breast cancer: An overview of the randomised trials
TL;DR: The absolute improvement in recurrence was greater during the first 5 years, whereas the improvement in survival grew steadily larger throughout the first 10 years, and these benefits appeared to be largely irrespective of age, menopausal status, daily tamoxifen dose, and of whether chemotherapy had been given to both groups.
Journal Article
Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group
TL;DR: There have been many randomised trials of adjuvant tamoxifen among women with early breast cancer, and an updated overview of their results is presented in this paper, which approximately doubles the amount of evidence from trials of about 5 years of tamoxifier and, taking all trials together, on events occurring more than 5 years after randomisation.
Journal ArticleDOI
Funnel plots for detecting bias in meta-analysis: guidelines on choice of axis.
TL;DR: In this paper, the authors evaluated standard error, precision (inverse of standard error), variance, inverse of variance, sample size and log sample size (vertical axis) and log odds ratio, log risk ratio and risk difference (horizontal axis).